Lv1
40 积分 2024-05-27 加入
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
5天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
6天前
已完结
Epidemiology of Sjögren syndrome
14天前
已完结
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
17天前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
1个月前
已完结
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
2个月前
已完结
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
2个月前
已完结
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
2个月前
已完结
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Consensus guideline for the management of colorectal cancer with peritoneal metastases
3个月前
已完结
皖公网安备34019202002308
